The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV‐infected patients on suppressive antiretroviral therapy

Novel Latency Reversal Agents for HIV-1 Cure

(2018) Adam M. Spivak et al.   Annual Review of Medicine

Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation

(2018) Qiyuan Kuai et al.   JOURNAL OF MEDICAL VIROLOGY

Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression

(2018) Thomas D. Zaikos et al.   JOURNAL OF VIROLOGY

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses

(2018) Christel Rothe Brinkmann et al.   mSphere

In vivo Administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals

(2018) Carolina Garrido et al.   AIDS

Low-dose chidamide restores immune tolerance in ITP patients and mice by modulating nTreg cells and CTLA4 expression

(2018) Hong-yu Zhao et al.   BLOOD

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

(2017) Nancie M. Archin et al.   JOURNAL OF CLINICAL INVESTIGATION

Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells

(2017) Yoshifumi Kobayashi et al.   JOURNAL OF GENERAL VIROLOGY

Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus

(2017) Wenqian Yang et al.   MICROBES AND INFECTION

HIV-1 envelope glycoprotein stimulates viral transcription and increases the infectivity of the progeny virus through the manipulation of cellular machinery

(2017) Xiaozhuo Ran et al.   Scientific Reports

Broad activation of latent HIV-1 in vivo

(2016) Kirston Barton et al.   Nature Communications

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function

(2016) G. Clutton et al.   Scientific Reports

Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function

(2016) Matthew Pace et al.   PLoS Pathogens

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function

(2016) Carolina Garrido et al.   Frontiers in Immunology

The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients

(2015) Anne Sofie Høgh Kølbæk Kjær et al.   AIDS

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study

(2015) Julian H Elliott et al.   Lancet HIV

HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat

(2014) N. M. Archin et al.   JOURNAL OF INFECTIOUS DISEASES

Eradicating HIV-1 infection: seeking to clear a persistent pathogen

(2014) Nancie M. Archin et al.   NATURE REVIEWS MICROBIOLOGY

Heat shock protein 90 controls HIV-1 reactivation from latency

(2014) I. Anderson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Drugging the HDAC6–HSP90 interplay in malignant cells

(2014) Oliver H. Krämer et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

(2014) Julian H. Elliott et al.   PLoS Pathogens

Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes

(2014) Richard Brad Jones et al.   PLoS Pathogens

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

Immune activation and HIV persistence: implications for curative approaches to HIV infection

(2013) Nichole R. Klatt et al.   IMMUNOLOGICAL REVIEWS

The end of AIDS: HIV infection as a chronic disease

(2013) Steven G Deeks et al.   LANCET

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

(2012) Mei Dong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation

(2012) Liang Shan et al.   IMMUNITY

An AP-1 Binding Site in the Enhancer/Core Element of the HIV-1 Promoter Controls the Ability of HIV-1 To Establish Latent Infection

(2012) A. Duverger et al.   JOURNAL OF VIROLOGY

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Shock and kill

(2012) Steven G. Deeks   NATURE

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

(2011) Zhi-Qiang Ning et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation

(2011) Matthew J Sweet et al.   IMMUNOLOGY AND CELL BIOLOGY

Unknown

(2011) Charles Dinarello et al.   MOLECULAR MEDICINE

NF-κB/Rel: agonist and antagonist roles in HIV-1 latency

(2010) Jonathan KL Chan et al.   Current Opinion in HIV and AIDS

A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression

(2009) K. S. Keedy et al.   JOURNAL OF VIROLOGY

Lysine Acetylation: Codified Crosstalk with Other Posttranslational Modifications

(2008) Xiang-Jiao Yang et al.   MOLECULAR CELL